No megadeals in biotech so far this yr, but on track for rec...
No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals,
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards Phase 2 Biotechs,
Big Pharma's spending patterns are shifting towards smaller bolt-on transactions that are earlier-stage,
There were 19 >$1 bil public biotech buyouts in 2023 w/ an avg deal size of $6.8 bil compared to 7 deals w/ an avg size of $2.5 bil in 2024...
In the first four months of 2024 56% of M&A deal dollar went towards Phase 2 Biotechs,
Big Pharma's spending patterns are shifting towards smaller bolt-on transactions that are earlier-stage,
There were 19 >$1 bil public biotech buyouts in 2023 w/ an avg deal size of $6.8 bil compared to 7 deals w/ an avg size of $2.5 bil in 2024...
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
